Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5985 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | AZD5985 |
| B | EXPERIMENTAL | placebo |
| Name | Type | Description |
|---|---|---|
| AZD5985 | DRUG | Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits. |
| placebo | DRUG | Oral suspension. |
Inclusion Criteria: * Provision of signed, written and dated informed consent prior to any study specific procedures. * Healthy male subjects aged 18 to 45 years (inclusive). * Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg. * Be non-smoker or ...
AZD5985 is an investigational small molecule drug developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial in healthy adult male volunteers in Germany. The specific disease or condition it is intended to treat has not been publicly disclosed.
AZD5985 is made by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the developer responsible for the clinical program for this investigational small molecule.
AZD5985 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this asset.
AZD5985 has been evaluated in one completed Phase 1 trial, NCT00799331, titled an Exploratory Study to Assess the Pharmacokinetics of AZD5985. The trial enrolled 32 healthy male volunteers aged 18 years and older in Germany and used a randomized, double-blind, controlled design.
AZD5985 is an investigational drug whose intended therapeutic use has not been publicly disclosed. Its only reported clinical study was conducted in healthy volunteers rather than in patients with a specific disease, which is typical of early Phase 1 pharmacokinetic research.